Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
about
Safety of L-proline as a stabilizer for immunoglobulin products.Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.Management of cutaneous dermatomyositis.A review on guidelines for management and treatment of common variable immunodeficiency.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?Managing patients with side effects and adverse events to immunoglobulin therapy.A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.Evidence that NF-κB and MAPK Signaling Promotes NLRP Inflammasome Activation in Neurons Following Ischemic Stroke.Measurement of Health-Related Quality of Life in Primary Antibody-Deficient Patients.Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients.Novel approaches in the treatment of myositis and myopathies.New Frontiers in Subcutaneous Immunoglobulin Treatment.Nanoscale reversed-phase liquid chromatography-mass spectrometry of permethylated N-glycans.Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.Economic burden of common variable immunodeficiency: annual cost of disease.Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.
P2860
Q37979844-AA94DFDF-80BA-45C7-A8CF-73366FFCCA9CQ38021422-69D54661-5F11-494A-B809-26320262C695Q38022271-8C188A7A-8CA6-4668-B6D2-0169A297433BQ38111423-30AD0460-E402-437F-BD44-23B30C172CFAQ38122120-FA6EA39A-3836-4A9C-B351-418E6F71F4D2Q38289442-60D97119-FBF8-4D26-97BA-A9FB4509E469Q38569717-195A48A1-DB40-4B44-A5DA-D969887916A4Q38614953-BAFB679B-1B95-40A1-BE7D-1B71F1A433D2Q38744512-9D1CAE68-AC11-4597-962B-A6F8CA5BE79AQ38769999-A23EB0AC-B5F0-424D-8360-B3CA9128660EQ40272358-60C4D771-A81D-4842-8F88-4B046C07F9ABQ41737545-831B8D93-7362-4932-ACC0-D66BE491BE26Q41977818-FC8F03E8-9981-4628-BBDE-0E6A6730A17EQ42775420-2A81F8DB-C7AE-4423-BA0A-3D3D36E343D2Q50497045-8B80E34F-AE78-4438-953F-1DF81A3290C9Q51151956-1121E6A3-34EC-410A-9040-EB40CD05BB30Q51276222-0DEE26C9-60C0-4EC4-AC19-447993B2134AQ55311044-4B509076-28A1-4869-99BE-7427488A95D6
P2860
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@en
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@nl
type
label
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@en
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@nl
prefLabel
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@en
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@nl
P2860
P50
P356
P1476
Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
@en
P2093
Hans D Ochs
P2860
P304
P356
10.1586/ECI.10.104
P577
2011-05-01T00:00:00Z